ClinicalTrials.gg

Program

E2511

A development code.

Its studies are mostly in Alzheimer Disease, led by Eisai.

Furthest: phase 1, since Sep 7, 20203 company-led studies, 1 open or runningNext primary completion: May 6, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai31 open or runningphase 1since Sep 7, 2020Sep 7, 2020May 6, 2030phase 1 · NCT07768592

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04547361 · 45 enrolled · United States
  2. Nov 24, 2021Phase 1 study in Healthy VolunteersNCT05147337 · 47 enrolled · United States
  3. Aug 12, 2026Phase 1 study in Alzheimer DiseaseNCT07768592 · 32 planned

Ahead

  1. May 6, 2030Primary completion: phase 1 study in Alzheimer DiseaseNCT07768592

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07768592Alzheimer Disease1Not yet recruitingMay 6, 203032
NCT05147337Healthy Volunteers · United States1CompletedAug 18, 202247
NCT04547361Healthy Volunteers · United States1CompletedMay 26, 202145

How it is read

Names in the registry

  • “E2511”, 3 entries

Codes read as this program: E2511.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.